偏头痛与心血管疾病风险:丹麦人群匹配队列研究
该研究为丹麦全国性人群匹配队列,纳入1995至2013年51 032例偏头痛患者及510 320例年龄、性别、日历年匹配的普通人群。随访19年后,偏头痛队列较普通人群每1000人累积发病率分别为:心肌梗死25 vs 17、缺血性卒中45 vs 25、出血性卒中11 vs 6、外周动脉疾病13 vs 11、静脉血栓栓塞27 vs 18、心房颤动或心房扑动47 vs 34、心力衰竭19 vs 18。校正合并症后,偏头痛与心肌梗死(调整HR 1.49,95%CI 1.36-1.64)、缺血性卒中(2.26,2.11-2.41)、出血性卒中(1.94,1.68-2.23)、静脉血栓栓塞(1.59,1.45-1.74)及心房颤动或心房扑动(1.25,1.16-1.36)正相关;与外周动脉疾病(1.12,0.96-1.30)和心力衰竭(1.04,0.93-1.16)无显著关联。关联在诊断后短期(0-1年)较长期(长达19年)更强,有先兆者较无先兆者更强,女性较男性更强;亚队列额外校正体重指数和吸烟后关联持续存在。
要点
- 偏头痛患者19年累积缺血性卒中为每1000人45例,普通人群为25例,调整HR 2.26(95%CI 2.11-2.41)。
- 偏头痛与出血性卒中调整HR 1.94(95%CI 1.68-2.23),心肌梗死调整HR 1.49(95%CI 1.36-1.64)。
- 偏头痛与静脉血栓栓塞调整HR 1.59(95%CI 1.45-1.74),心房颤动或心房扑动调整HR 1.25(95%CI 1.16-1.36)。
- 外周动脉疾病(调整HR 1.12,95%CI 0.96-1.30)和心力衰竭(1.04,0.93-1.16)与偏头痛无显著关联。
- 关联在诊断后0-1年较长达19年随访更强,有先兆者较无先兆者更强,女性较男性更强。
适用人群与场景
- 丹麦全国1995至2013年所有医院及医院门诊的51 032例偏头痛患者,与按年龄、性别、日历年匹配的510 320例普通人群比较。
研究设计与关键结果
- 研究类型为全国性人群匹配队列研究,纳入51 032例偏头痛患者和510 320例普通人群对照,随访长达19年。
- 随访19年每1000人累积发病率:心肌梗死偏头痛组25 vs 普通人群17,缺血性卒中45 vs 25,出血性卒中11 vs 6,外周动脉疾病13 vs 11,静脉血栓栓塞27 vs 18,心房颤动或心房扑动47 vs 34,心力衰竭19 vs 18。
- 校正合并症后,偏头痛与心肌梗死(调整HR 1.49,95%CI 1.36-1.64)、缺血性卒中(2.26,2.11-2.41)、出血性卒中(1.94,1.68-2.23)、静脉血栓栓塞(1.59,1.45-1.74)及心房颤动或心房扑动(1.25,1.16-1.36)正相关。
- 偏头痛与外周动脉疾病(调整HR 1.12,95%CI 0.96-1.30)和心力衰竭(1.04,0.93-1.16)无显著关联。
- 关联在诊断后短期(0-1年)较长期(长达19年)更强,有先兆者较无先兆者更强,女性较男性更强。
- 亚队列额外校正体重指数和吸烟后,关联持续存在。
证据类型、等级与局限
- 证据类型为全国性人群匹配队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为偏头痛可能是大多数心血管疾病的重要危险因素。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To examine the risks of myocardial infarction, stroke (ischaemic and haemorrhagic), peripheral artery disease, venous thromboembolism, atrial fibrillation or atrial flutter, and heart failure in patients with migraine and in a general population comparison cohort.
DESIGN: Nationwide, population based cohort study.
SETTING: All Danish hospitals and hospital outpatient clinics from 1995 to 2013.
PARTICIPANTS: 51 032 patients with migraine and 510 320 people from the general population matched on age, sex, and calendar year.
MAIN OUTCOME MEASURES: Comorbidity adjusted hazard ratios of cardiovascular outcomes based on Cox regression analysis.
RESULTS: Higher absolute risks were observed among patients with incident migraine than in the general population across most outcomes and follow-up periods. After 19 years of follow-up, the cumulative incidences per 1000 people for the migraine cohort compared with the general population were 25 v 17 for myocardial infarction, 45 v 25 for ischaemic stroke, 11 v 6 for haemorrhagic stroke, 13 v 11 for peripheral artery disease, 27 v 18 for venous thromboembolism, 47 v 34 for atrial fibrillation or atrial flutter, and 19 v 18 for heart failure. Correspondingly, migraine was positively associated with myocardial infarction (adjusted hazard ratio 1.49, 95% confidence interval 1.36 to 1.64), ischaemic stroke (2.26, 2.11 to 2.41), and haemorrhagic stroke (1.94, 1.68 to 2.23), as well as venous thromboembolism (1.59, 1.45 to 1.74) and atrial fibrillation or atrial flutter (1.25, 1.16 to 1.36). No meaningful association was found with peripheral artery disease (adjusted hazard ratio 1.12, 0.96 to 1.30) or heart failure (1.04, 0.93 to 1.16). The associations, particularly for stroke outcomes, were stronger during the short term (0-1 years) after diagnosis than the long term (up to 19 years), in patients with aura than in those without aura, and in women than in men. In a subcohort of patients, the associations persisted after additional multivariable adjustment for body mass index and smoking.
CONCLUSIONS: Migraine was associated with increased risks of myocardial infarction, ischaemic stroke, haemorrhagic stroke, venous thromboembolism, and atrial fibrillation or atrial flutter. Migraine may be an important risk factor for most cardiovascular diseases.
参考来源
- Adelborg K, Szépligeti SK, Holland-Bill L, et al. Migraine and risk of cardiovascular diseases: Danish population based matched cohort study. BMJ. 2018. PMID: 29386181. doi:10.1136/bmj.k96
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。